Clinical trials: Corneal Endothelial Decompensation
Diabetes Mellitus, Corneal Endothelial Cell Loss
Effect of Intracameral Dexamethasone After Phacoemulsification in Diabetics on Corneal Endothelial Cell Density
The prevalence of diabetes mellitus (DM) is rapidly growing worldwide. One major concern with diabetes mellitus is how it may affect vision in different ways; including the increased risk of developing cataract.
- Conditions
- Diabetes Mellitus, Corneal Endothelial Cell Loss, Dexamethasone Adverse Reaction, Corneal Endothelial Decompensation
- Trial name
- DIABEDEX (NCT03361709)
- Testing
- Dexamethasone, Saline Solutions, Intraocular
- Sponsor
- Cairo University
Fuchs Endothelial Corneal Dystrophy, Corneal Endothelial Decompensation
Effect of Donor Diabetes and Other Factors on Corneal Transplant Endothelial Cell Loss and Success at 5 Years
This multi-center clinical trial is designed to assess the association of diabetes in a cornea donor with transplant success and loss of endothelial cells 5 years following Descemet membrane endothelial keratoplasty (DMEK).
- Trial name
- DEKS (NCT07217249)
- Testing
- Descemet membrane endothelial keratoplasty
- Where
- 14 sites in United States
- Volunteers
- 570 people
- Sponsor
- Case Western Reserve University
Corneal Endothelial Decompensation, Fuchs' Endothelial Dystrophy
Impact of Donor Diabetes on DMEK Success and Endothelial Cell Loss
This double-masked multi-center trial will evaluate the association of diabetes in the cornea donor with transplant success and loss of endothelial cells through 1 year following Descemet membrane endothelial keratoplasty (DMEK).
- Trial name
- DEKS (NCT05134480)
- Testing
- Descemet membrane endothelial keratoplasty
- Where
- 2 sites in United States
- Volunteers
- 1,097 people
- Sponsor
- Case Western Reserve University
Mild to Moderate Corneal Endothelial Decompensation, Bullous Keratopathy
Safety and Efficacy of Tissue Engineered Endothelial Keratoplasty
Assessment of safety and efficacy of tissue-engineered corneal endothelial graft material generated using cultured human corneal endothelial cells for tissue-engineered endothelial keratoplasty (TE-EK).
- Conditions
- Mild to Moderate Corneal Endothelial Decompensation, Bullous Keratopathy, Fuchs' Endothelial Dystrophy, Post-surgical Corneal Decompensation (Irreversible)
- Trial name
- TE-EK (NCT04319848)
- Testing
- TE-EK treatment group
- Where
- Singapore
- Volunteers
- 30 people
- Sponsor
- Singapore Eye Research Institute
Fuchs Dystrophy, Corneal Edema
A Comparison Between Full Thickness and Partial Thickness Corneal Transplantation for Corneal Edema
The objectives of this study are to compare the visual and refractive outcomes of deep lamellar endothelial keratoplasty (DLEK) with penetrating keratoplasty as treatment for certain cases of corneal edema due to endothelial…
- Trial name
- NCT00346138
- Testing
- Corneal transplantation
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Mayo Clinic
Fuchs' Endothelial Dystrophy, Phacoemulsification
Fuchs' Torsional Phaco Study
The primary objective is to compare the effect of torsional phacoemulsification and longitudinal phacoemulsification on central and peripheral corneal thickness/volume after cataract surgery in patients with Fuchs' endothelial…
- Trial name
- NCT00781027
- Testing
- Phacoemulsification
- Where
- Netherlands
- Volunteers
- 50 people
- Sponsor
- Maastricht University Medical Center
Corneal Edema, Corneal Endothelial Dysfunction
Study of Safety and Tolerability of EO2002 in the Treatment of Corneal Edema
Corneal edema is the most common indication for corneal transplantation, accounting for approximately 70% of penetrating keratoplasty (PK), and 100% of endothelial keratoplasty (EK) procedures annually.
- Conditions
- Corneal Edema, Corneal Endothelial Dysfunction, Corneal Endothelial Dystrophy, Fuchs Dystrophy
- Trial name
- NCT04894110
- Testing
- EO2002, EO2002 low dose, EO2002 mid dose
- Where
- 8 sites in United States
- Volunteers
- 42 people
- Sponsor
- Emmecell
Corneal Edema, Fuchs
Study of EO2002 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction
This study will evaluate the safety and effectiveness of a single injection of EO2002 at one of two dose levels (150,000 or 500,000 magnetic human corneal endothelial cells [mHCECs]), compared with a placebo injection, in…
- Conditions
- Corneal Edema, Fuchs, Fuchs Dystrophy, Fuchs' Endothelial Dystrophy
- Trial name
- EMERALD (NCT07729137)
- Testing
- 150K cells, 500K cells
- Where
- 10 sites in United States
- Volunteers
- 121 people
- Sponsor
- Emmecell